Excessive intramedullary apoptosis is central in the pathogenesis of myelodysplastic syndromes (MDS). Growth-inhibiting cytokines, the Fas/FasLigand pathway, and autoreactive cytotoxic T-lymphocytes have been identified to be important proapoptotic factors in MDS. In normal hematopoiesis, a4b1 and a5b1 integrin-mediated interactions between progenitors and fibronectin are critical for progenitor cell survival. In this study, we have used flow cytometry to quantify the expression levels of members of the b1 integrin family on CD34 þ marrow progenitors in 27 untreated patients with MDS, three with s-AML, and 25 control subjects. In MDS, we observed that nonapoptotic progenitors significantly downregulate cell surface expression levels of a4 and b1 integrin chains compared with healthy controls. Downregulation of a4, b1, and also a5 was present in MDS patients with Z25% apoptotic progenitors, irrespective of their French, American, British subcategory. Reduced cell surface expression levels of a4, a5, and b1 did also correlate with decreased in vitro adhesiveness to fibronectin fragments. Therefore, our observations suggest that downregulation of a4b1 and a5b1 integrins on CD34 þ progenitors could be a newly identified proapoptotic mechanism in MDS.
Introduction
Hematopoiesis occurs in close contact with a protective and permissive microenvironment consisting of a variety of cellular elements, extracellular matrix components, and membrane-bound and soluble cytokines. Contact-mediated interactions between hematopoietic progenitor cells (HPC) and stromal ligands play an important role in the orderly regulation of the hematopoietic process. Hematopoietic precursors interact with the extracellular matrix through a variety of cell surface adhesion receptors including selectins, the immunoglobulin-like superfamily, cell surface proteoglycans, cadherins, and integrins. [1] [2] [3] [4] Integrins are heterodimeric transmembrane cell surface glycoproteins consisting of a noncovalently linked a and b chain. There are at least 18 a and eight b subunits, giving rise to more than two dozen distinct integrins in mammalian cells. 2, 5, 6 The b1 family of integrins is attributed a predominant role in the retention of hematopoietic progenitors in the bone with fibronectin, laminin, and collagen as their principal ligands. 2, 7 In addition to providing an anatomical linkage, integrins also play a critical role in communication between cells and their microenvironment, and in intercellular crosstalk. Several studies have proven that survival, proliferation and differentiation of HPC is dependent on a4b1 (or VLA-4) and a5b1 (or VLA-5) integrin-mediated interactions between progenitors and fibronectin. [8] [9] [10] [11] A 75 kDa proteolytic fragment in the center of the fibronectin molecule contains the peptide RGD and interacts with most cells via the a5b1 integrin receptor. Adhesion to fibronectin can also occur in an RGD-independent manner via the 33/66 kDa COOH-terminal 'heparin-binding domain' containing the minimal recognition site for the a4b1 integrin receptor. 2 Stimulation of a4b1 integrin receptors by adhesion to the COOH-terminal heparin-binding domain of fibronectin, 9 or by direct monoclonal antibody crosslinking, 12 inhibits proliferation of normal clonogenic and immature hematopoietic progenitors by blocking transition from the G1 to S phase of the cell cycle. Interactions between a5b1 10 or a4b1 11 and fibronectin are also important in rescuing cells, including HPC, from apoptosis. As a consequence, the expression levels and/or functional status of b1 integrins, and more precisely a4b1 and a5b1, are important regulators of the survival and proliferation of normal HPC. The interactions between a4b1 and a5b1 receptors on leukemic cells and their stromal ligands have also been intensively studied both in acute and chronic leukemia. [13] [14] [15] [16] [17] For example, the interaction of a4b1 with fibronectin has been shown to promote the survival of AML blasts, and may therefore be of crucial importance in the persistence of minimal residual disease. 13 Given their importance in normal and leukemic hematopoiesis, we were interested in the expression and function of a4b1 and a5b1 on HPC in myelodysplastic syndromes (MDS): a bone marrow failure disorder with a high propensity for leukemic transformation. Although peripheral blood cytopenia is a common feature in MDS, the bone marrow is frequently found to be hypercellular. Increased intramedullary apoptosis associated with progenitor hyperproliferation is the commonly accepted explanation for this paradox. 18, 19 Apoptosis in MDS is generally accepted to be multifactorial in origin. 20 Cumulated genomic damage in HPC, 21 an imbalance between growthand apoptosis-promoting cytokines like TNF-a, 22 activation of the Fas/FasL pathway, 23 and increased numbers of autoreactive cytotoxic T-lymphocytes 24 all can promote MDS apoptosis to a variable extent. If quantitative and/or functional abnormalities in the integrins of the b1 family, like a4b1 and a5b1, are involved in apoptosis induction and/or hyperproliferation of MDS progenitor cells, is to the best of our knowledge currently unknown.
In this study, we have measured the expression levels of the a4b1 and a5b1 integrin cell surface receptors on MDS-derived CD34 þ marrow progenitors and studied their relationship with levels of intramedullary apoptosis and disease subtype. (Table 1) Fresh bone marrow aspirates were consecutively obtained from 27 unselected patients with MDS and three with secondary AML. Patients were either in chronic follow-up or newly referred to our center. Mean patient age was 67 years (range 30-85 years). According to the French, American, British (FAB) morphological guidelines for MDS classification, 10 patients had RA, five RARS, five RAEB, and seven RAEB-t. A cytogenetic abnormality was observed in 16/27 patients. None of the patients had received anti-MDS therapy other than supportive care for at least 4 weeks prior to the bone marrow examination. In all, 25 healthy volunteer bone marrow donors served as controls.
Materials and methods

Patient characteristics
Progenitor isolation
Bone marrow aspirations and sample handlings were performed in accordance with the guidelines of the local ethical committee of the Catholic University Leuven. Bone marrow samples were aspirated from the posterior iliac crest and collected in syringes prefilled with phosphate-buffered saline (PBS) and preservativefree heparin. All samples were processed immediately. Mononuclear cells were recovered after centrifugation for 30 min at 1400 rpm on a Lymphoprep gradient (1.077 g/ml; Nycomed Pharma AS, Oslo, Norway). Subsequently, mononuclear cells were washed twice in PBS supplemented with 0.3% bovine serum albumin (Sigma Chemical Co, St Louis, MO, USA) and kept on ice until CD34 selection. CD34 enrichment was carried out by a double passage over MiniMACS CD34 isolation columns (Miltenyi Biotec, Bergish Gladbach, Germany) according to the manufacturer's instructions.
Flow cytometry
CD34
þ cells were resuspended in PBS and split equally into snap cap tubes at a final concentration of 50 000 cells/100 ml. Cells were incubated for 30 min at 41C with phycoerythrin (PE)-conjugated monoclonal antibodies against the following adhesion receptor chains: b1 or CD29 (clone MAR4), a2 or CD49b (clone 12F1-H6), a4 or CD49d (clone 9F10), a5 or CD49e (clone IIA), and a6 or CD49f (clone GOH3). Cells stained with PE-conjugated isotype-specific antibodies were used as negative controls. All antibodies were purchased from Pharmingen (Becton Dickinson). After incubation, cells were washed with 1 ml cold HEPES binding buffer (10 mM HEPES, (pH ¼ 7.4), 140 mM NaCl, 5 mM CaCl 2 ), and pelleted cells were resuspended in 100 ml of HEPES buffer. Subsequently, 5 ml of fluorescein isothiocyanate (FITC)-conjugated annexin V (Clontech Laboratories, Palo Alto, CA, USA) and 1 ml of 7-aminoactinomycin D (7-AAD at 157 mM) (Calbiochem, La Jolla, CA, USA) were added, followed by incubation for 10 min at room temperature in the dark. Subsequently, cells were kept on ice and flow cytometric analysis was carried out within 1 h. Threecolor analysis was performed on a FACScan flow cytometer (Becton Dickinson, San Diego, CA, USA) equipped with a 488 nm argon-ion laser and a standard filter combination provided by the manufacturer. Electronic compensation was population. For each antibody tested, we have used the distribution histogram to determine the geometric mean of the fluorescence intensity (MFI) (Figure 1b) . 25 The degree of positivity for each tested surface adhesion receptor was expressed as a numerical ratio calculated by dividing the MFI of the positively stained cells by that of cells stained with the isotype-matched control antibody.
Adhesion assays
For functional adhesion tests, we have used fibronectin fragments as adhesive ligands. Previously published methodology was slightly adapted in order to allow more accurate quantification of adherent cells. In summary, 24-well flatbottomed tissue culture plates were coated overnight at 371C with HBF (human fibronectin a-chymotryptic 40 K fragment, concentration 25 mg/ml, Gibco BRL, Life Technologies Ltd, Paisley, Scotland) containing the a4b1 high-affinity region CS-1 (the minimal recognition site for the a4b1 integrin), and with the peptide RGD (fibronectin-like engineered protein polymer, concentration 25 mg/ml, Sigma, St Louis, USA) containing the a5b1-binding domain. After overnight incubation, plates were washed twice with PBS to remove unbound protein, and remaining nonspecific protein binding sites were blocked for 1 h at 371C with 5% BSA in PBS. Before plating the cells, excess BSA was removed by washing with PBS. Control wells were coated overnight with 5% BSA. After coating and washing, 50 000 CD34 þ cells resuspended in 1 ml of PBS were allowed to adhere for 1 h at 371C. Each experiment was performed in duplicate. Nonadherent cells were removed by three consecutive gentle washes with PBS. After the final wash, 1 ml of prewarmed trypsin-EDTA (Gibco BRL) was added to each well to detach the adherent cells. After 10 min at 371C, 1 ml of icecold fetal bovine serum (StemCell Technologies, Vancouver, BC, Canada) was added to neutralize trypsin activity. The adherent cells were collected and microscopic inspection ensured that all adherent cells were recovered from the wells. Subsequently, adherent and nonadherent cells were washed separately, pelleted by centrifugation, and resuspended in 200 ml HEPES buffer. Adherent and nonadherent cells were counted by flow cytometry using TruCount s Absolute Count Tubes (Becton Dickinson). Briefly, cells were added to the TruCount s tubes and stained with 10 ml CD34 PE, 5 ml annexin V FITC, and 1 ml of 7-AAD, followed by incubation for 15 min at room temperature in the dark. The absolute number of adherent cells was obtained with the following formula: ((number of events in cell containing region/number of events in absolute count bead region) Â total number of beads per test). The percentage of adherent cells could be subsequently calculated.
Statistical analysis
For statistical calculations, we have used GraphPad PRISM version 3.02. Values of adhesion receptors are expressed as the ratio of the MFI7s.e.m. Comparison between the expression levels of adhesion receptors was carried out using the MannWhitney test. Correlations were calculated with the Spearman rank test. Statistical significance in other experiments was calculated using a two-tailed Student's t-test. In all statistical calculations, a P-value of o0.05 was considered significant.
Results
Levels of apoptosis in MDS patients and controls
As shown in Figure 2a , levels of apoptosis in purified CD34 þ progenitors were significantly higher in MDS patients (n ¼ 30) (mean ¼ 26.7%; range ¼ 1.5-70.9%) compared to control subjects (n ¼ 25) (mean ¼ 9.7%; range ¼ 2.5-20.7%) (P ¼ 0.005). Patients with RA, RARS (early phase MDS, n ¼ 15) displayed significantly higher levels of apoptosis (mean ¼ 38%; (Figure 2b ). Using the apoptosis levels in the control population as reference values, we have defined two MDS subgroups for the purpose of this study. Patients with o25% of their CD34 þ population being apoptotic were considered to have 'low apoptosis MDS' (LA-MDS; n ¼ 18) (mean ¼ 10.5%; range ¼ 1.5-21.1%) and had apoptosis levels in the range of the control population, whereas patients with Z 25% apoptotic progenitors are referred to as 'high apoptosis' MDS (HA-MDS; n ¼ 12) (mean ¼ 51%; range ¼ 32.3-70.9%). In the early phase MDS subgroup, 9/15 patients fell within the HA-MDS subcategory, whereas this was limited to only 3/15 patients with more advanced MDS subtypes.
Expression levels of adhesion receptors on normal and MDS CD34
þ progenitors
In order to avoid any possible influence of the apoptotic process itself on cell membrane adhesion receptors, we have only reported expression levels of adhesion receptors after gating on the viable annexin V neg /7-AAD neg CD34 þ progenitor fractions. As explained in the Materials and methods section, levels of adhesion receptors were expressed using a ratio between the MFI of the antibody directed against the adhesion receptor and an isotype-matched control antibody. Comparing these ratios between all MDS patients and control subjects, we observed a significant decreased expression of b1 or CD29 (4. (Figure 3a) . Adhesion receptor expression on CD34 þ progenitors from control subjects and MDS patients. Highly purified CD34 þ cells were incubated with PE-conjugated monoclonal antibodies against CD29 (or b1), CD49d (or a4), CD49e (or a5), CD49b (or a2), and CD49f (or a6). Cells incubated with PE-conjugated isotype-specific antibodies were used as negative controls. Analyses were carried out on a FACScan flow cytometer. A minimum of 20 000 events was analyzed for each sample, and gating was performed on the annexin V neg /7-AAD neg CD34 þ population. We have used the distribution histogram to determine the geometric MFI. The degree of positivity for each tested surface adhesion receptor was expressed as a ratio calculated by dividing the MFI of the positively stained cells by that of cells stained with the isotype-matched control antibody. Results are expressed as mean values7s.e.m. (a) MDS patients (n ¼ 30) vs control subjects (n ¼ 25). [8] [9] [10] [11] [12] [13] [14] [15] [16] .33]) was also observed, but not in a statistically significant way (P ¼ 0.1 for both) (Figure 3b ). An inverse correlation was found between the percentage of apoptosis and the expression levels of CD49d (r ¼ À0.4).
When patients were grouped according to their FAB subtype, MDS-derived progenitors from patients with early phase MDS (RA, RARS) had a significant downregulation of CD49e (4. (Figure 3c ). When a comparison was made between LA-MDS patients in the early (n ¼ 6) and advanced MDS subgroups (n ¼ 12), expression levels of CD29 (7. [1.60-4 .98]) compared with the LA-MDS subpopulation within the same FAB subgroups (n ¼ 6, cfr. supra). Although P-alues were found to be o0.05, we believe these sample numbers are too small to perform mathematically correct statistical comparisons.
a4b1 and a5b1-mediated adhesion of CD34 þ MDS progenitors on fibronectin fragments
In the next set of experiments, we have studied the relationship between the expression levels of the adhesion receptors CD29, CD49d, and CD49e on CD34
þ MDS progenitors and their in vitro adhesive capacity to their natural ligands: the fibronectin fragments HBF and RGD. In nine patients, we obtained sufficient progenitors to perform functional adhesion tests. CD34 þ progenitors were plated on purified HBF (ligand for a4b1) and RGD (ligand for a5b1), with BSA as control. The percentage of adhesion was quantified as described in the Materials and methods section, and correlated with the measured baseline expression levels of CD29, CD49d, and CD49e. The mean percentage of adhesion to HBF was 34% (range: 11-65%), and 42% (range: 21-65%) for RGD. The mean percentage of adhesion to BSA varied between 8 and 10% (mean ¼ 9%) and was significantly lower compared to HBF and RGD peptide (P ¼ 0.001 for both). We observed a positive correlation between the expression levels of CD49d and CD29 on MDS CD34 þ progenitors and their individual adhesive capacity to HBF (r ¼ 0.6 and 0.9, respectively). Similar observations were made between expression levels of CD49e, CD29, and adhesion on RGD (r ¼ 0.3, and r ¼ 0.7, respectively) ( Figure 4 ). These data suggest that decreased expression of CD29, CD49d, and CD49e is associated with a reduced in vitro adhesive capacity to fibronectin fragments.
Discussion
Excessive intramedullary programmed cell death or apoptosis is central in the pathogenesis of MDS. Although it can affect all FAB subtypes, literature evidence points towards higher levels of intramedullary apoptosis in patients with a low propensity for leukemic transformation (RA, RARS). 26 Our findings are in Relationship between expression levels of CD29, CD49d, CD49e and adhesion on HBF (a) and RGD (b) fibronectin fragments. Functional adhesion tests were performed in nine MDS patients by plating 50 000 CD34 þ cells in 24-well flat-bottomed tissue culture plates overnight coated with purified fibronectin fragments HBF (ligand for a4b1) and RGD (ligand for a5b1), with BSA as control. After adhesion for 1 h at 371C, nonadherent and adherent cells were recovered, washed, and enumerated by flow cytometry using TruCount s Absolute Count Tubes (Becton Dickinson). Subsequently, the percentage of adherent cells could be calculated. r-values are the Spearman correlation coefficients. Regression lines were fitted by Graphpad PRISM version 3.02.
Expression of a4b1 and a5b1 integrins in myelodysplasia M Delforge et al support of these published observations: in comparison with the RA and RARS subgroups (early phase MDS), apoptosis levels of progenitor cells from patients with RAEB, RAEB-t, and sAML (advanced MDS) were significantly lower and in the range of what was observed in a control population. Currently, it is still a matter of debate if apoptosis in MDS is fundamentally related to the molecular pathogenesis of the disease or if it is merely a 'logical' consequence of progressive damage to genes and proteins essential for cell proliferation and survival. Additionally, the currently known proapoptotic triggers are not always identifiable in every individual MDS patient, so the challenge to unravel new proapoptotic factors in MDS still remains. The importance of a4b1-and a5b1-mediated interactions between progenitor cells and the extracellular matrix in the proliferation, differentiation, and survival of normal and leukemic progenitors has inspired us to study b1 integrin expression levels on MDSderived progenitors. By comparing a randomly selected group of 30 untreated MDS patients with healthy control subjects, we have observed a significantly decreased expression of the b1 and a4 integrin chains on the cell surface of marrow-derived CD34 þ MDS progenitors. On contrary, a2 and a6 were found to be upregulated, albeit not significantly. In other words, these observations give evidence for selective downregulation of a4b1 integrins on CD34 þ progenitors in MDS patients. Given the elevated progenitor apoptosis levels in the overall MDS study population, and the established antiapoptotic role of a4b1, we were intrigued if our observation of downregulation of a4b1 could be related to the apoptotic process itself. Therefore, we have performed a reanalysis by grouping patients based on their levels of progenitor apoptosis. In the patient subgroup with apoptosis levels higher than what could be observed in a randomly selected healthy control population (what we called 'high apoptosis' MDS), we observed a significant downregulation of a4, b1, and also of a5 integrin chains in comparison with MDS patients having apoptosis levels within the range of the control population (so-called 'low apoptosis' MDS). Similar significancies were found when comparing high apoptosis patients and control subjects, but not between low apoptosis patients and controls (results not shown). In contrast, when patients were grouped according to their FAB subtypes into early phase MDS (RA, RARS) and advanced MDS (RAEB, RAEBt, and sAML), we found only a significant downregulation of a5 in the early phase MDS subgroup. However, it has to be considered that within this early phase MDS subgroup, 40% of the patients belonged to the low apoptosis subcategory, and their expression of a4, b1, and a5 was fully in the range of what could be observed in the majority of advanced MDS patients and the controls. In contrast, the 60% of early phase patients with high apoptosis levels had an overt downregulation of a4, b1, and a5 in comparison with their low apoptosis counterparts. In other words, our results suggest that the downregulation of a4, b1, and a5 is more related to the levels of progenitor cell apoptosis and not primarily to the FAB subtype.
Our observations raise the question as to what mechanisms could underlie the downregulation of adhesion receptors, and more precisely of a4b1 and a5b1, on progenitor cells in MDS.
It is well known that apoptosis and cell death cause cell membrane disintegration and protein cleavage. 27 Therefore, in order to avoid any interference from the apoptotic process itself on our results, we have performed all flow cytometric analyses after gating on viable, nonapoptotic, progenitors only. The annexin V assay that we used to discriminate viable and apoptotic cells measures the translocation of phosphatidylserine from the inner leaflet of the plasma membrane to the outer surface. This is a characteristic early change in apoptotic cells occurring prior to the loss of cell membrane integrity and nucleosomal DNA fragmentation. 28 Therefore, it seems very unlikely that the adhesion receptor downregulation on MDS progenitors that we observed would be a consequence of an already advanced apoptotic process. In contrast, our observations of reduced a4b1 and a5b1 expression levels would rather support the concept that this downregulation is not a consequence of the apoptotic process itself, but eventually a newly identified proapoptotic trigger in MDS. Cell death caused by decreased adhesion to stromal ligands is called anoikis 29 and is primarily controlled by the ECM in a a4b1 and a5b1 integrin-specific manner. 10, 11 In our functional adhesion studies, we observed that decreased expression levels of a4, a5, and b1 integrin chains did correlate with reduced in vitro adhesiveness to fibronectin fragments, their principal natural ligands. These in vitro findings might support the concept that a4b1 and a5b1 downregulation on hematopoietic progenitors from MDS patients could exert its proapoptotic effect by decreased in vivo adhesiveness to the extracellular matrix component fibronectin.
Progenitor hyperproliferation, frequently observed concomitantly with apoptosis in MDS, 30 could also be related to decreased a4b1 or a5b1 expression, but was beyond the scope of our present study.
Since it is very unlikely that the apoptotic process itself is responsible for a4b1 and a5b1 downregulation, the possible underlying mechanisms still need to be elucidated. Intrinsic structural abnormalities in cell membrane proteins or exogenous microenvironmental factors like impaired cytokine production could be responsible for adhesion receptor downregulation. Altered cell surface receptor expression has already been sporadically reported in MDS. 31 Additionally, a recent report has shown that patients with less advanced (RA/RARS) and more advanced MDS subtypes (RAEB and RAEBt) can be discriminated using cell surface immunophenotyping. 32 On the other hand, it is well known that several cytokines can influence the number and/or the ligand binding affinity of members of the b1 integrin family. Both in normal and in AML progenitor cells, cytokines like IL-3, GM-CSF, and SCF can upregulate the functional state of a4b1 and a5b1 integrins, resulting in increased adhesion to fibronectin. 14, 33 Growthinhibiting cytokines like TNF-a and IFN-g are known to promote cell death in MDS by several mechanisms. 34, 35 Although they can also modulate the expression of adhesion receptors, 36 it is to be elucidated if they also contribute to altered a4b1 and a5b1 expression levels in MDS.
Finally, despite the predominant clonal nature of hematopoiesis in MDS, the possibility remains that the CD34 þ fractions of MDS patients with early phase disease (RA, RARS) could still contain minor nonclonal fractions. 37, 38 This is a drawback of many MDS studies when separation of clonal and nonclonal progenitors is not possible. Nevertheless, we believe that minor nonclonal fractions could only result in neglectable variations of the highly significant differences in a4b1 and a5b1 expression levels we observed in this study.
In summary, we have shown that CD34 þ progenitor cells from MDS patients with high levels of intramedullary apoptosis have a significant downregulation of the a4b1 and a5b1 integrin receptors. Given the importance of these particular integrin receptors in cell survival, this downregulation could be a newly identified proapoptotic factor in MDS. Reduced adhesion to the extracellular matrix component fibronectin might be the principal mechanism by which a4b1 and a5b1 downregulation reduces progenitor cell survival.
